Compare VS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VS | CALC |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 7.6M |
| IPO Year | 2017 | 2020 |
| Metric | VS | CALC |
|---|---|---|
| Price | $0.74 | $1.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 12.3K | ★ 62.6K |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,183,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3711.30 | N/A |
| 52 Week Low | $0.70 | $0.44 |
| 52 Week High | $1.86 | $72.00 |
| Indicator | VS | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 31.82 | 41.27 |
| Support Level | N/A | $1.08 |
| Resistance Level | $1.18 | $1.84 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 15.14 | 8.81 |
Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.